Folura™: A Guide to Menopause Hair Thinning and Hair Changes

A guide for women navigating hair changes through the peri- and post-menopausal transition, with an honest look at what the research does and doesn’t show.

The short answer: Menopause hair thinning is often tied in part to hormonal change. During the transition, estrogen falls faster than androgens do, so androgens carry relatively more influence at the scalp (Torréns et al., 2009). Folura™ is a once-daily vegan softgel with 160 mg of Serevelle™ saw palmetto extract, the dose used in a 180-day placebo-controlled trial in which the active group, half of them women, had greater gains in hair counts and density than placebo (Ablon, 2026). A subgroup of menopausal women in that trial also showed significant gains in terminal hair count and density compared with placebo.* Changes build over three to six months of daily use.

You’ve been feeding the hair you already have. The change starts somewhere else.

You’ve watched your part widen. You’ve bought the gummies, the collagen powder, maybe an expensive-looking bottle of something with “hair, skin and nails” on the label. And somewhere around month four you started wondering whether any of it was ever going to do anything.

That’s a fair question. For many women, the honest answer is that those products weren’t designed around what’s happening at the follicle during the menopausal transition.

Folura™ works differently. It’s a single-active hair density softgel built around Serevelle™ saw palmetto extract at 160 mg, which is the exact dose used in a published, placebo-controlled clinical trial (Ablon, 2026), paired with 232 mg of pumpkin seed oil. Folura™ works at the root of thinning, using an extract studied for its role in the DHT pathway and shown in a placebo-controlled trial to support hair counts and density.* If you’re the kind of person who wants to know exactly what you’re swallowing and why, this one is easy to audit.

Folura™ at a glance

·       What’s in it: 160 mg Serevelle™ saw palmetto extract (the studied dose) plus 232 mg pumpkin seed oil. Nothing hidden in a proprietary blend.

·       Who was studied: Adults with self-perceived thinning hair, half of them women, with a separate analysis in menopausal women.

·       How you take it: One vegan softgel a day with a meal.

·       How long to give it: Three to six months of consistent use.

·       What it costs: $29.95 for a 30-day bottle, just under $1 a day.

How a Follicle-Focused Approach Supports Fuller, Thicker Hair Through the Menopausal Transition*

One studied active at the researched dose, in a single daily softgel, built around research that enrolled women rather than extrapolated from a men’s-only study.

Folura™ is a single-active hair density softgel from Triquetra Health. Every softgel carries 160 mg of Serevelle™ proprietary saw palmetto extract (Serenoa repens, fruit), the dose used in published research, providing 105 mg of the ActiLipid4Hair™ bioactive fatty acid complex (Ablon, 2026). Alongside it sits 232 mg of pumpkin seed oil (Cucurbita pepo), which serves as the oil base of the softgel.

Serevelle™ was evaluated in a 180-day randomized, double-blind, placebo-controlled trial in adults with self-perceived thinning hair (Ablon, 2026; registered on ClinicalTrials.gov as NCT06920758 under the ingredient’s earlier name, USPlus® DERM).

What makes it worth a look if you’re in perimenopause or past it: a disclosed single active at the studied dose, one softgel a day, and a clinical dataset where women made up half the participants and menopausal women got their own subgroup analysis, with significant gains in terminal hair count and density versus placebo.*

Menopause Hair Thinning Isn’t Random, and It Isn’t Your Fault

Your hair has been part of who you are for decades. Watching it thin during a life stage that already feels destabilizing lands harder than most people outside it understand.

You notice the scalp under bright bathroom light. You notice it in the group photo somebody took from above. Then you start angling away from certain lighting without quite admitting to yourself that’s what you’re doing.

You’re also not unusual. In one clinic-based study of postmenopausal women, about half (52.2%) had female-pattern thinning (Chaikittisilpa et al., 2022).

And the products have felt wrong. Many “women’s hair” formulas are built on biotin and vitamins. And much of the research on saw palmetto, the botanical most associated with the DHT pathway, was done in men.

So here’s a reframe worth sitting with. For many women this pattern is connected to hormonal change, and that change registers at the follicle. It isn’t a character flaw or a failure of effort. It’s biology, and biology is something you can work with.

Why Were Most Hair Vitamins Designed for a Different Problem?

Most products marketed to women for hair fall into three broad buckets, and most of them aren’t built around the follicle-level DHT pathway that researchers link to hormonally influenced thinning.

Worth saying plainly before we go further: oral hair supplements as a category aren’t worthless. A 2026 systematic review and meta-analysis of 14 studies covering 967 participants found improvements versus placebo on several hair-cycle and shedding endpoints, though not on total hair count (p = 0.06), and the authors called for more independent research (Alanazi et al., 2026). The question isn’t whether these products do anything. It’s whether they’re aimed at what’s changing for you.

Take the biotin, collagen and multivitamin products first. They’re appealing because they feel like low-risk daily insurance. But biotin deficiency is uncommon in well-nourished adults, and published reviews have found little evidence that biotin supplementation helps hair in people who aren’t deficient (NIH Office of Dietary Supplements, 2022; Patel et al., 2017; Yelich et al., 2024). These products address a nutritional pathway, which is a different target than the hormonal changes of the menopausal transition.

Multi-ingredient “hair wellness” blends make a more sophisticated pitch. They tell a “root causes” story, but they often combine many ingredients, sometimes in a proprietary blend that doesn’t list the saw palmetto form or amount, so you can’t compare it to any single-ingredient study. Some of these blends have been tested as whole formulas, which is worth acknowledging (Ablon & Kogan, 2018, 2021). What you can’t do is tell which ingredient is doing the work. Multi-capsule routines also add up over a three-to-six-month window.

Then there are marine-protein hair supplements. They’re pleasant to take, they’re popular, and credit where it’s due: they’re among the better-studied options in the category, including a company-sponsored randomized trial in women that reported improved hair counts and reduced shedding (Ablon, 2015). The distinction isn’t that they lack evidence. It’s that they’re built around a nutrient and protein pathway rather than the follicle-level DHT pathway.

All three were built for a different problem. That’s not a knock on them, it’s a mismatch. If hormonal change is part of your picture, the sharper question is what supports the follicle where that change actually registers.

What Happens at the Follicle During Menopause, and How Does Folura™ Work?

During the menopausal transition, estrogen falls faster than androgens do. In the SWAN cohort of 1,862 women, estradiol declined about 12.0% per year while testosterone declined about 3.1% per year, so the testosterone-to-estrogen ratio rose roughly 10.1% per year (Torréns et al., 2009). Your total testosterone doesn’t necessarily rise. What changes is the ratio (Gupta et al., 2025).

With less estrogen to oppose them, androgens carry relatively more influence at the scalp. In follicles that are genetically susceptible, testosterone gets converted to DHT by the 5-alpha-reductase enzyme, DHT binds androgen receptors, and those follicles start producing finer hairs that cycle out sooner (Ntshingila et al., 2023; Ramos & Miot, 2015). That’s the short version of why a nutrition-only approach may not match what’s happening here.

One caveat belongs right up front, because you’ll find it in the literature and you deserve to hear it from us first: the role of androgens in women’s hair thinning is less clearly established than it is in men (Ramos & Miot, 2015; Gupta et al., 2025). Researchers are still sorting out how much of menopausal thinning is androgen-related versus estrogen-withdrawal-related.

 

 

 

With that said, here’s how each ingredient in Folura™ fits the follicle story.

1. Studied in the DHT pathway

In laboratory testing on human dermal papilla cells (a type of hair follicle cell), the extract inhibited 5-alpha-reductase, the enzyme that converts testosterone to DHT, with an IC50 of 0.39 µg/mL (Broadley et al., 2026).* The human trials measured hair counts and density, not DHT levels. Lab findings describe a mechanism and don’t by themselves predict what happens in a person.

2. Studied in the hair growth phase

Beyond the DHT pathway, the extract has been studied in ex vivo human hair follicles, where the same formulation was associated with roughly a 30% increase in the proportion of follicles in the anagen (active growth) phase (Ablon, 2026; Broadley et al., 2026). Those follicles were donated by men and grown in the lab without testosterone. This is a laboratory observation in cultured tissue, not a clinical outcome.

3. A complementary oil base

Pumpkin seed oil (232 mg) is the oil the extract is delivered in. It naturally contains phytosterols, plant compounds that have been examined in laboratory research for their interaction with 5-alpha-reductase (Hosking et al., 2019). Human hair research on pumpkin seed oil is limited (see below), so we treat it as a complementary ingredient, not a second clinically dosed active.

Here’s the mechanism story without the polish: saw palmetto’s relevance to hair rests on the DHT pathway, and the clinical outcomes below come from human research in the exact form and dose in Folura™. What you’re choosing is a studied form at a studied dose, aimed at the follicle, where menopausal change registers.

What Can a Follicle-Focused Approach Mean for Your Daily Life?

Biology matters because of what it looks like in an ordinary week.

Watching for early signs

Shedding was one of several measures in the Serevelle™ trial. At Day 90, the active group showed a small but statistically significant drop in hairs released on a standardized pull test compared with baseline (Ablon, 2025).* Participants’ own ratings of shedding did not favor the active group over placebo, so we’d treat shedding as a secondary signal. The more reliable measures in the trial were hair counts and density, which take three to six months to build.

The part line that stops catching the light

Give it three to six months. Over that window, the goal is increased hair density so the part looks fuller and the scalp is less visible.* It builds over time. Gradual and cumulative, not overnight.

The photo you don’t angle around

For most women the real outcome isn’t a number on a lab printout. It’s not quietly reorganizing your social life around lighting and camera angles. One visible thing moving in the right direction, during a stage when plenty of things feel like they’re moving the other way.

Your three-to-six-month plan

In the trial, measurable changes were documented at Day 90 and the advantage over placebo kept widening through Day 180.* That timeline gives you a simple plan:

·       Day 1: Take a scalp photo of your part in steady daylight, from the same angle you’ll use every month.

·       Months 1 to 2: One softgel daily with a meal. This stretch is mostly about building the habit, so don’t judge results yet.

·       Month 3: Compare your photos. The trial’s first measurable changes were documented around this point.

·       Months 4 to 6: Keep going. In the trial, the gap versus placebo kept widening through Day 180.

One bottle is a 30-day supply, so a full run is three to six bottles, at about $1 a day. Consistency across the full window is the part that matters most.

What Does the Clinical Research Show, and What Doesn’t It?

Serevelle™ has published, placebo-controlled human data in the exact form and dose used in Folura™. Here’s a straight accounting, including the parts that don’t flatter us.

The primary trial

 

 

You may also see these results described as “283% / 414% / 306% greater improvement” versus placebo. Those figures come from the published paper, but they look large partly because the placebo group declined. The clearer takeaway is the direction: the active group gained where the placebo group lost ground.

The menopausal-women subgroup

The published 180-day paper reports a subgroup analysis in menopausal women, in which Serevelle™ produced statistically significant placebo-adjusted gains in total terminal hair count (p < 0.05) and total hair density (p < 0.01).* The advantage for total vellus hair count in this subgroup was numerical but did not reach statistical significance. This is a genuine published subgroup finding, and it is still a subgroup of a 60-person trial, not a dedicated study in menopausal women.

The 90-day interim

Ablon (2025), Journal of Cosmetic Dermatology, 24(12), e70585, reported significant improvements in terminal hair count versus both baseline and placebo in anterior and posterior scalp areas, plus significant anterior vellus hair gains.* The 180-day paper later reported that the advantage over placebo kept widening through Day 180 (Ablon, 2026).

Pumpkin seed oil

Pumpkin seed oil has been tested in one 24-week RCT: in 76 men with hereditary-pattern hair thinning, blinded investigators rated 44.1% of the active group as improved versus 7.7% on placebo (Cho et al., 2014).* Three honest qualifications: the study product also contained other plant ingredients, so the result can’t be attributed to pumpkin seed oil alone (Hosking et al., 2019); it used 400 mg daily, more than the 232 mg in Folura™; and it enrolled men only.

What the research doesn’t establish, stated plainly

This is a single, small, industry-funded trial (funded by the ingredient maker, Valensa International; registered on ClinicalTrials.gov as NCT06920758 under the ingredient’s earlier name, USPlus® DERM). It studied the ingredient, not the finished Folura™ product, and the trial used a bovine gelatin softgel while Folura™ uses a vegan softgel. Longer-term data beyond 180 days isn’t yet available, and the menopausal-women results come from a subgroup of this small trial rather than a dedicated study, which means they should be read as encouraging and exploratory, not definitive. No treatment-related adverse events were reported in the published trial. Folura™ is described as clinically studied, not “clinically proven.”

See the full Folura™ label and pricing → 

What Makes Folura™ Different?

If you’re weighing options, here are the trade-offs laid out honestly.

For female-relevant evidence: Folura™ is built on an active whose placebo-controlled trial enrolled women as half its participants and reported a separate analysis in menopausal women. That’s different from saw palmetto research that enrolled men only.

For dose transparency: A single disclosed active at the 160 mg studied dose. Compare that with multi-ingredient proprietary blends that don’t list the saw palmetto dose, or generic saw palmetto that discloses a dose but isn’t the specific form used in the Serevelle™ trials.

For a follicle-focused approach: An approach oriented around the hormonal pathway at the follicle, rather than a nutritional one.* Folura™ is a dietary supplement, not a drug, and it isn’t a substitute for any treatment your clinician has recommended. If you already follow a provider-directed routine, ask your clinician whether adding a supplement makes sense for you.

For simplicity: One softgel a day. A simple routine is easier to keep up over the three-to-six-month window that matters.

For formulation: A vegan softgel built on pea starch and glycerin, with no gelatin. Worth knowing if you’ve had to skip hair supplements before: many softgels use animal gelatin (the softgel in the Serevelle™ trial was bovine gelatin), and marine-protein hair products may contain shellfish-derived ingredients.

For supplier quality: Serevelle™ is produced by Valensa International, whose separate USPlus® saw palmetto extract was the first saw palmetto ingredient to complete USP’s Ingredient Verification Program for Dietary Ingredients (Nutraceutical Business Review, n.d.; United States Pharmacopeia, n.d.). That verification applies to Valensa’s USPlus® ingredient, not to Serevelle™ or to Folura™ itself, but it’s a meaningful signal of the supplier’s quality systems in a category where adulterated extracts have been documented in the ingredient supply chain (Gafner & Baggett, 2018).

None of this says the other products are bad. It says Folura™ occupies a specific, defensible position: a single disclosed active, at the studied dose, with human data that included women.

 

Your Questions, Answered

How is this different from the hair vitamins I’ve already tried?

Most hair vitamins supply nutrients like biotin and collagen, which address a nutritional pathway rather than the follicle-level hormonal pathway. Folura™ works at the root of thinning, using an extract studied for its role in the DHT pathway and shown in a placebo-controlled trial to support hair counts and density.* You get a single disclosed active at the dose used in published research instead of a multi-ingredient stack. Different mechanism, different part of the picture.

Was Folura™ actually studied in women?

Yes, with an honest caveat. The 180-day randomized, placebo-controlled trial of Serevelle™ enrolled both men and women, with women making up half the participants, which already sets it apart from saw palmetto research that enrolled men only. The paper also reports a menopausal-women subgroup, where the active showed significant placebo-adjusted gains in terminal hair count and total hair density.* It’s a subgroup of a 60-person trial rather than a dedicated menopausal-women study, so the fair statement is “studied in research that included women,” not “proven for every woman.”

How long until I notice a difference?

Changes build gradually. In the Serevelle™ trial, measurable gains in hair counts and density were documented at Day 90, and the difference versus placebo kept widening through Day 180.* Plan on three to six months of consistent daily use before judging results. One practical tip: take a monthly scalp photo in the same lighting, from the same angle. Memory is a terrible instrument for this. Photos aren’t.

How much does Folura™ cost, and is there a guarantee?

One bottle holds 30 softgels, a one-month supply, for $29.95, which works out to about $1 a day. Because results are judged over three to six months, a full run is three to six bottles. Full terms are on the product page.

Is Folura™ suitable for vegans or people with allergies?

The softgel is vegan, made with pea starch and glycerin rather than gelatin, and the formula is soy free, gluten free and non-GMO. It contains no marine or shellfish-derived ingredients. The full ingredient list is on the label, with nothing hidden behind a proprietary blend.

Can I take Folura™ with my other menopause supplements or medications?

Saw palmetto is generally well tolerated in research, and no treatment-related adverse events were reported in the published Serevelle™ studies. Talk with your healthcare provider before starting Folura™, especially if you take a blood thinner or antiplatelet medication, use hormone therapy or hormonal birth control, take a prescription for hair thinning, or have surgery scheduled. Do not use during pregnancy or while breastfeeding.

A Fuller-Looking Part Line, Supported at the Follicle*

If the hair vitamins you’ve tried haven’t matched what you’re experiencing, one reason may be that many were built around a nutritional pathway rather than a hormonal one. For some women, a follicle-focused approach may be a better fit.

Folura™ gives you a single studied active at the researched dose, in one daily vegan softgel, backed by published human data that included women and a separate look at menopausal women. We’ve laid out the limits of that evidence above, because we’d rather you start with clear expectations than feel misled six months from now. Individual results vary.

If that sounds like what you’ve been looking for, the next step is simple: one softgel a day, a monthly photo, and three to six months to see where it takes you.

Start your first three months with Folura™ → Full terms are on the product page.

For the Detail-Oriented: Ingredients, Dose, and Safety

Serevelle™ proprietary saw palmetto extract, 160 mg

A concentrated bioactive fatty acid extract of Serenoa repens (fruit), produced by a proprietary supercritical carbon dioxide process without cosolvents, standardized to four free fatty acids (the ActiLipid4Hair™ complex, 105 mg per serving). Same form, same dose used in the Ablon 90-day and 180-day publications (Ablon, 2025; Ablon, 2026). Studied in laboratory research for its interaction with 5-alpha-reductase, and evaluated in placebo-controlled human trials measuring hair counts and density.* Sourced from Valensa International, whose separate USPlus® saw palmetto extract was the first of its kind to complete USP’s Ingredient Verification Program, which is notable because adulterated saw palmetto extracts have been documented in the ingredient supply chain (Gafner & Baggett, 2018).

Pumpkin seed oil (Cucurbita pepo), 232 mg

Contains naturally occurring phytosterols and serves as the oil base of the softgel. The amount here is complementary and is not intended to replicate the dose used in published research.

Other ingredients

Pea starch, glycerin, carrageenan, disodium phosphate and purified water. That’s the entire vegan softgel shell. Nothing else is in the formula.

Dose, format and supply

Take one softgel daily with a meal. Thirty softgels per bottle, which is a one-month supply. Full dose transparency: every ingredient and amount is disclosed, with no proprietary blend.

Certifications

Vegan, soy free, gluten free and non-GMO. Third-party tested and manufactured under GMP standards.

Safety and interactions

Saw palmetto is generally well tolerated in research (NCCIH, 2025), and no treatment-related adverse events were reported across the published Serevelle™ studies (Ablon, 2025; Ablon, 2026). Talk with your healthcare provider before starting Folura™, especially if you take a blood thinner or antiplatelet medication, use hormone therapy or hormonal birth control, take a prescription for hair thinning, or have surgery scheduled (Memorial Sloan Kettering Cancer Center, 2023). The Serevelle™ trial excluded people who had recently started or changed hormonal birth control or hormone therapy, and people using anti-androgens or 5-alpha-reductase inhibitors (ClinicalTrials.gov NCT06920758). Do not use during pregnancy or while breastfeeding. It’s formulated for adults 18 and over.

When Is Folura™ the Right Fit, and When Isn’t It?

It’s worth considering when a woman is experiencing menopause hair thinning and wants a follicle-focused approach rather than another biotin stack; when she values evidence that included women and full dose transparency; and when simplicity (one softgel daily) supports staying consistent through the three-to-six-month window.

It may not be the right fit when thinning is clearly linked to a diagnosed medical condition, a medication, or a nutritional deficiency that’s better addressed with a clinician; when a woman prefers a topical-only routine or is already well served by a provider-directed protocol; or during pregnancy or while breastfeeding.

The honest bottom line: Folura™ is a well-formulated, transparent, single-active option with published clinical support in the exact form and dose it contains. It’s a reasonable, evidence-informed choice for the right person, and we’d rather you make that call with clear eyes than with hype.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult your healthcare provider before starting any new supplement regimen.

Clinical findings described above are from published studies on the Serevelle™ saw palmetto extract ingredient and on a pumpkin-seed-oil supplement, not on the finished Folura™ product.

Scientific References & Citations

Ablon, G. (2015). A 3-month, randomized, double-blind, placebo-controlled study evaluating the ability of an extra-strength marine protein supplement to promote hair growth and decrease shedding in women with self-perceived thinning hair. Dermatology Research and Practice, 2015, 841570. https://doi.org/10.1155/2015/841570

Ablon, G. (2025). The safety and efficacy of a proprietary bioactive fatty acids extract from saw palmetto (Serenoa repens) for promoting hair growth and reducing hair loss in adults with self-perceived thinning hair: 90-day results. Journal of Cosmetic Dermatology, 24(12), e70585. https://doi.org/10.1111/jocd.70585

Ablon, G. (2026). The safety and efficacy of a novel saw palmetto (Serenoa repens) extract for promoting hair growth in adults with self-perceived thinning hair: 180-day results. Journal of Cosmetic Dermatology, 25(2), e70717. https://doi.org/10.1111/jocd.70717

Ablon, G., & Kogan, S. (2018). A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. Journal of Drugs in Dermatology, 17(5), 558-565. https://pubmed.ncbi.nlm.nih.gov/29742189/

Ablon, G., & Kogan, S. (2021). A randomized, double-blind, placebo-controlled study of a nutraceutical supplement for promoting hair growth in perimenopausal, menopausal, and postmenopausal women with thinning hair. Journal of Drugs in Dermatology, 20(1), 55-61. https://doi.org/10.36849/JDD.5701

Alanazi, R., Alshammari, S., Aldossari, K., Alwatban, R., Aljeribah, D., Alanazi, S., Alsalhi, A., Alhumam, A., & Alajlan, A. (2026). Evaluating the effectiveness of commercial oral supplements for hair growth: A systematic review and meta-analysis. Journal of Cosmetic Dermatology, 25(4), e70817. https://doi.org/10.1111/jocd.70817

Broadley, D., Le Riche, A., Guénin, S., Jimenez, F., Vinocur, L., Edelkamp, J., & Bertolini, M. (2026). A proprietary lipidosterolic extract of Serenoa repens promotes hair growth through mechanisms that extend beyond 5-alpha reductase inhibition: Insights from human hair follicle organ culture. International Journal of Cosmetic Science, 48(2), 352-366. https://doi.org/10.1111/ics.70035

Chaikittisilpa, S., Rattanasirisin, N., Panchaprateep, R., Orprayoon, N., Phutrakul, P., Suwan, A., & Jaisamrarn, U. (2022). Prevalence of female pattern hair loss in postmenopausal women: A cross-sectional study. Menopause, 29(4), 415-420. https://doi.org/10.1097/GME.0000000000001927

Cho, Y. H., Lee, S. Y., Jeong, D. W., Choi, E. J., Kim, Y. J., Lee, J. G., Yi, Y. H., & Cha, H. S. (2014). Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: A randomized, double-blind, placebo-controlled trial. Evidence-Based Complementary and Alternative Medicine, 2014, 549721. https://doi.org/10.1155/2014/549721

Gafner, S., & Baggett, S. (2018). Adulteration of saw palmetto (Serenoa repens) (Version 3). Botanical Adulterants Prevention Bulletin. ABC-AHP-NCNPR Botanical Adulterants Prevention Program. https://umb.herbalgram.org/media/ceqeziln/bap-babs-sawpalmetto-cc-102018-v3.pdf

Gupta, A. K., Economopoulos, V., Mann, A., Wang, T., & Mirmirani, P. (2025). Menopause and hair loss in women: Exploring the hormonal transition. Maturitas, 198, 108378. https://doi.org/10.1016/j.maturitas.2025.108378

Hosking, A.-M., Juhasz, M., & Atanaskova Mesinkovska, N. (2019). Complementary and alternative treatments for alopecia: A comprehensive review. Skin Appendage Disorders, 5(2), 72-89. https://doi.org/10.1159/000492035

Memorial Sloan Kettering Cancer Center. (2023, October 16). Saw palmetto. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/saw-palmetto

National Center for Complementary and Integrative Health. (2025, April). Saw palmetto: Usefulness and safety. U.S. Department of Health and Human Services. https://www.nccih.nih.gov/health/saw-palmetto

National Institutes of Health, Office of Dietary Supplements. (2022, January 10). Biotin: Fact sheet for health professionals. U.S. Department of Health and Human Services. https://ods.od.nih.gov/factsheets/Biotin-HealthProfessional/

Ntshingila, S., Oputu, O., Arowolo, A. T., & Khumalo, N. P. (2023). Androgenetic alopecia: An update. JAAD International, 13, 150-158. https://doi.org/10.1016/j.jdin.2023.07.005

Nutraceutical Business Review. (n.d.). USPlus saw palmetto by Valensa achieves USP verified status. https://nutraceuticalbusinessreview.com/usplus-saw-palmetto-by-valensa-achieves-usp-verified-status-156486

Patel, D. P., Swink, S. M., & Castelo-Soccio, L. (2017). A review of the use of biotin for hair loss. Skin Appendage Disorders, 3(3), 166-169. https://doi.org/10.1159/000462981

Ramos, P. M., & Miot, H. A. (2015). Female pattern hair loss: A clinical and pathophysiological review. Anais Brasileiros de Dermatologia, 90(4), 529-543. https://doi.org/10.1590/abd1806-4841.20153370

Torréns, J. I., Sutton-Tyrrell, K., Zhao, X., Matthews, K., Brockwell, S., Sowers, M., & Santoro, N. (2009). Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: Study of Women’s Health Across the Nation. Menopause, 16(2), 257-264. https://doi.org/10.1097/gme.0b013e318185e249

U.S. National Library of Medicine. (n.d.). A 6-month, randomized, double-blind, placebo controlled study evaluating the efficacy and safety of USPlus DERM to promote hair growth in men and women with self-perceived thinning hair (Identifier NCT06920758). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06920758

United States Pharmacopeia. (n.d.). Verification program participants. https://www.usp.org/verification-services/verification-program-participants

Yelich, A., Jenkins, H., Holt, S., & Miller, R. (2024). Biotin for hair loss: Teasing out the evidence. The Journal of Clinical and Aesthetic Dermatology, 17(8), 56-61. https://pmc.ncbi.nlm.nih.gov/articles/PMC11324195/